Therapeutic efficacy of lamivudine in preventing the activity of hepatitis B virus in perioperative patients with hepatocellular carcinoma / 中国实用外科杂志

ABSTRACT

ObjectiveTo study the therapeutic efficacy of lamivudine in preventing the activity of hepatitis B virus in patients with hepatocellular carcinoma and hepatitis B virus infection. MethodsFrom March 1999 to March 2000,72patients with hepatocellular carcinoma and hepatitis B virus infection were divided into 2 groups in complete randomization. In group 1,38 patients were treated with lamivudine 100mg/qd during perioperative period. Before and after operation,we detected HBV DNA with assay of quantitative polymerase chain reaction (QPCR). The control group(2) wasn't given anti-hepatitis B virus treatment. ResultsThe results showed that in group 2,the copies of HBV DNA in sera one week,two weeks after operations were significantly higher than those before the operation(P<0.01);in group 1,the copies of HBV DNA in sera one week,two weeks after operations were significantly lower than those before operation(P<0.01),all within the safety threshold;between group 1 and group 2,the indexes of ALT in sera and Child status didn't significantly change before and after operation.The postoperative complications were significantly different two weeks after operation.Conclusion It suggests that surgical interventions may result in promoting the process of HBV replication,the activity of HBV infection should be treated in perioperation, and the replication of HBV can be inhibited by lamivudine safely to the safety threshold within a short time, though lamivudine doesn't improve the liver biochemistry significantly.